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Introduction {#sec1}
============

Loss of function and/or mass of insulin-producing pancreatic β-cells is a hallmark of both type 1 and 2 diabetes (T1D/T2D) ([@bib9], [@bib37], [@bib48], [@bib67], [@bib83]). Pancreatic β-cell death is a critical pathogenic factor contributing to the declined β-cell mass in both T1D and T2D ([@bib4], [@bib9], [@bib37], [@bib46], [@bib47], [@bib48], [@bib52], [@bib64], [@bib67], [@bib80]). Also, β-cell dedifferentiation ([@bib12], [@bib34], [@bib77]) and impaired adaptive proliferation ([@bib3], [@bib79]) have been proposed as potential additional causes for this diminished β-cell mass in diabetes. Although immune-cell-mediated events predominate in T1D ([@bib10]), metabolic factors such as elevated levels of glucose, fatty acids, and islet amyloid polypeptide (IAPP), alongside with pro-inflammatory cytokines, drive β-cell loss and dysfunction in T2D ([@bib1], [@bib2], [@bib18], [@bib25], [@bib31], [@bib44], [@bib62], [@bib69], [@bib89]). Excessive β-cell death is commonly seen in the islets of both patients with T1D and lean and obese patients with T2D as determined by multiple complementary approaches ([@bib9], [@bib47], [@bib52], [@bib80]). Counter-intuitively, higher levels of β-cell apoptosis in autopsy pancreases from patients with established diabetes inversely correlate with the insulin-positive β-cell area. But even at a pre-diabetic stage, i.e., in at-risk individuals who progressed to T1D, β-cell death is evident and accompanied with diminished insulin secretion ([@bib28]). Correspondingly, in patients with impaired glucose tolerance before T2D diagnosis, loss of β-cells is apparent and correlates with elevated fasting glucose levels ([@bib68]); this gradually progresses when hyperglycemia is established and β-cells are unable to sustain insulin production under a higher metabolic demand. Indeed, pancreatic β-cells show a relatively higher susceptibility to apoptosis together with lower stress-induced protective responses compared with many other cell types, including the neighboring pancreatic α-cells. For instance, a recent proteomic analysis shows a very weak induction of β-cell\'s reactive oxygen species (ROS)-detoxifying enzymes in response to inflammatory assault ([@bib22]). This confirms previous observations showing very low levels of protective anti-oxidative enzymes in β-cells ([@bib23], [@bib38], [@bib39], [@bib78]). Consistently, human β-cells are much more sensitive to apoptosis than α-cells in response to T2D-related metabolic stressors ([@bib45]). All these seem to represent an "Achilles heel" through which diabetogenic stimuli trigger rapid β-cell death and accelerate the collapse in response to environmental stress and demand.

The ubiquitin-proteasome system (UPS) is a highly regulated key intracellular protein degradation pathway, which consists of an enzymatic cascade controlling protein ubiquitination and has important functions in several essential biological processes, such as cell survival, proliferation, development, and DNA damage response (DDR) ([@bib73]). The UPS is a process of post-translational modification of targeted protein by covalent attachment of one or more ubiquitins to lysine residues by an *E3* ubiquitin ligase. This is antagonized by enzyme deubiquitinases (DUBs), such as ubiquitin-specific proteases (USPs). The UPS is primarily responsible for the degradation and clearance of misfolded or damaged proteins as well as of dysfunctional organelles, which compromise cellular homeostasis. Abnormalities in the UPS machinery have been linked to the pathogenesis of many diseases, including cancer, immunological and neurological disorders ([@bib20], [@bib73], [@bib91]), as well as β-cell failure in diabetes ([@bib7], [@bib8], [@bib14], [@bib13], [@bib27], [@bib30], [@bib35], [@bib41]). A member of the USP family, ubiquitin-specific protease 1 (USP1), is one of the best known DUBs responsible for removing ubiquitin from target proteins and thus influences several cellular processes such as survival, differentiation, immunity and DDR ([@bib21], [@bib40], [@bib85]). Although USP1 was initially identified as a novel component of the Fanconi anemia DNA repair pathway ([@bib55]), extensive subsequent studies revealed a pleotropic function of USP1 and identified novel interacting partners and signaling for USP1 action and regulation in normal physiological conditions and in disease states such as tumorigenesis ([@bib21], [@bib40], [@bib85]). An array-based assay identified reduced USP1 mRNA expression in islets from patients with T2D ([@bib8]). As the consequent effects of USP1 in diabetes and especially in the pancreatic β-cell were completely unknown so far, we investigated the role and the mechanism of action of USP1 on β-cell survival under diabetic conditions using clonal β-cells and isolated primary human islets. Although USP1 protein expression was unchanged in a diabetic milieu, we identified a robust protective effect on β-cell survival by USP1 inhibition.

Results {#sec2}
=======

USP1 Knockdown Protects β-cells from Apoptosis Under Diabetic Conditions {#sec2.1}
------------------------------------------------------------------------

Transcriptome analysis of islets isolated from healthy individuals as well as from patients with T2D showed consistent alteration of genes of UPS components, including members of the USP family such as USP1 ([@bib8]). Because USP1 is involved in signaling pathways associated with DDR and survival ([@bib40]), we aimed here to identify whether USP1 regulates apoptosis in β-cells under diabetogenic conditions. USP1 was expressed in protein lysates extracted from both human and mouse islets (data not shown) and INS-1E cells ([Figure 1](#fig1){ref-type="fig"}). The total protein level was not significantly changed in response to a pro-diabetic milieu in INS-1E cells ([Figure 1](#fig1){ref-type="fig"}). To evaluate the function of USP1 in the regulation of β-cell survival, USP1 was depleted in rat INS-1E β-cells by transfection with siUSP1 ([Figure S1](#mmc1){ref-type="supplementary-material"}) and thereafter cultured long term with high glucose concentrations (glucotoxicity; [Figures 1](#fig1){ref-type="fig"}A and 1B), a combination of high glucose with saturated free fatty acid palmitate (glucolipotoxicity; [Figures 1](#fig1){ref-type="fig"}C and 1D), and a cocktail of pro-inflammatory cytokines (interleukin-1 beta \[IL-1β\], interferon gamma \[IFN-γ\], and tumor necrosis factor alpha \[TNF-α\]; [Figures 1](#fig1){ref-type="fig"}E and 1F). Consistent with our previous observations, long-term culture with elevated glucose, glucose/palmitate, and cytokines robustly induced β-cell apoptosis ([@bib4], [@bib87], [@bib88]). Knockdown of USP1 markedly reduced the levels of glucose-, glucose/palmitate-, and cytokine-induced apoptosis as indicated by decreased levels of hallmarks of apoptosis, namely, caspase-3 and its downstream target poly(ADP-ribose) polymerase (PARP) cleavage ([Figures 1](#fig1){ref-type="fig"}A--1F). These data indicate that loss of USP1 confers apoptosis resistance to β-cells against stress-induced cell death.Figure 1USP1 Knockdown Protects β-Cell from Apoptosis Under Diabetic Conditions(A--F) INS-1E cells were seeded at 300,000 cells/well and transfected with either control scrambled siRNA (siScr) or siRNA specific to USP1 (siUSP1) and treated with (A and B) 22.2 mM glucose (HG), (C and D) a mixture of 22.2 mM glucose and 0.5 mM palmitate (HG/Pal), or (E and F) pro-inflammatory cytokines (2 ng/mL recombinant human IL-1β, 1000 U/mL TNF-α, and 1000 U/mL IFN-γ; Cyto) for 2 days. Representative Western blots (A, C, and E) and quantitative densitometry analysis (B, D, and F) of cleaved caspase 3 (Cl Casp3) and cleaved PARP (Cl PARP) protein levels are shown. Data are pooled from at least three independent cell line experiments. Data show means ±SEM. \*p \< 0.05 siScr treated compared with siScr control conditions. \*\*p \< 0.05 siUSP1-treated compared with siScr-treated conditions. ^\#^p = 0.05 compared with HG (B) or Cyto (F). See also [Figure S1](#mmc1){ref-type="supplementary-material"} for USP1 quantification.

Small Molecule USP1 Inhibitors Block β-Cell Apoptosis Under Diabetic Conditions {#sec2.2}
-------------------------------------------------------------------------------

Several USP1 small molecule inhibitors have been developed recently. Quantitative high-throughput screen and subsequent medicinal chemistry identified compound ML323 ([Figure 2](#fig2){ref-type="fig"}A) as a highly potent selective inhibitor of USP1 with excellent specificity, when compared with other DUBs, deSUMOylase, deneddylase, and unrelated proteases ([@bib17], [@bib40]). ML323 was able to potently inhibit USP1 activity in a dose-dependent manner in several complementary *in vitro* assays as well as in cellular models as represented by increased monoubiquitination of USP1 known substrates proliferating cell nuclear antigen (PCNA) and Fanconi anemia group D2 protein (FANCD2) ([@bib17], [@bib40]). Inhibition of USP1 was also confirmed in INS-1E cells treated with ML323 as indicated by the accumulation of ubiquitinated PCNA, a USP1 downstream substrate ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). To confirm the anti-apoptotic action of USP1 loss obtained by the genetic approach, we used ML323 to block USP1 activity in INS-1E cells exposed to diabetic conditions. USP1 inhibition by ML323 at two concentrations (5 and 10 μM), which proved to be non-toxic at basal levels (data not shown), potently inhibited the induction of caspase-3 and PARP cleavage triggered by elevated glucose ([Figures 2](#fig2){ref-type="fig"}B and 2C), glucose/palmitate ([Figures 2](#fig2){ref-type="fig"}D and 2E), and cytokines ([Figures 2](#fig2){ref-type="fig"}F and 2G), further demonstrating the pro-apoptotic activity of USP1 in the presence of the diabetic milieu. Also, by using an ubiquitin-rhodamine-based high-throughput screening, Mistry et al. identified SJB2-043 ([Figure 3](#fig3){ref-type="fig"}A) as another potent selective small-molecule inhibitor of USP1. SJB2-043 blocked the deubiquitinating enzyme activity of USP1 *in vitro* with an IC50 in the nanomolar range ([@bib53]). To further confirm the utility of USP1 blockade in protecting β-cells from apoptosis, we tested the effect of SJB2-043 on β-cell survival in the presence of diabetogenic conditions. Consistent with our genetic and pharmacological approaches using siRNA against USP1 and the USP1 inhibitor ML323, USP1 inhibition by SJB2-043 at two concentrations (20 and 50 nM) attenuated β-cell apoptosis as represented by the robust reduction of cleaved caspase-3 and PARP induced by glucotoxicity ([Figures 3](#fig3){ref-type="fig"}B and 3C), glucolipotoxicity ([Figures 3](#fig3){ref-type="fig"}D and 3E), and pro-inflammatory cytokines ([Figures 3](#fig3){ref-type="fig"}F and 3G). Altogether, small molecule inhibitors of USP1 improved β-cell survival under diabetic conditions and recapitulated the β-cell protective effect of USP1 silencing.Figure 2USP1 Inhibitor ML323 Blocks β-Cell Apoptosis Under Diabetic Conditions(A) Chemical structure of ML323.(B--G) About 500,000 INS-1E cells/well treated with or without USP1 inhibitor ML323 were exposed to 22.2 mM glucose (HG; B and C), a mixture of 22.2 mM glucose and 0.5 mM palmitate (HG/Pal; D and E), or pro-inflammatory cytokines (2 ng/mL recombinant human IL-1β, 1000 U/mL TNF-α, and 1000 U/mL IFN-γ; Cyto; F and G) for 2 days. Representative Western blots and quantitative densitometry analysis of cleaved caspase 3 (Cl Casp3) and cleaved PARP (Cl PARP) protein levels are shown. Data are pooled from at least three independent cell line experiments. Data show means ±SEM. \*p \< 0.05 treated compared with control conditions. \*\*p \< 0.05 inhibitor-treated compared with treated conditions. ^\#^p = 0.05 compared with HG/P (E) or untreated control (G) alone. See also [Figure S2](#mmc1){ref-type="supplementary-material"} for PCNA ubiquitination.Figure 3USP1 Inhibitor SJB2-043 Blocks β-Cell Apoptosis Under Diabetic Conditions(A) Chemical structure of SJB2-043.(B--G) About 500,000 INS-1E cells/well treated with or without USP1 inhibitor SJB2-043 were exposed to 22.2 mM glucose (HG; B and C), a mixture of 22.2 mM glucose and 0.5 mM palmitate (HG/Pal; D and E), or pro-inflammatory cytokines (2 ng/mL recombinant human IL-1β, 1000 U/mL TNF-α, and 1000 U/mL IFN-γ; Cyto; F and G) for 2 days. Representative Western blots and quantitative densitometry analysis of cleaved caspase 3 (Cl Casp3) and cleaved PARP (Cl PARP) protein levels are shown. Data are pooled from at least three independent cell line experiments except for cl PARP in C (n = 2). Data show means ±SEM. \*p \< 0.05 treated compared with control conditions. \*\*p \< 0.05 inhibitor-treated compared with treated conditions. ^\#^p = 0.05 compared with Cyto (G) alone.

USP1 Inhibition Protects Human Islets from Apoptosis without Compromising Their Insulin Secretory Function {#sec2.3}
----------------------------------------------------------------------------------------------------------

To test the efficacy of USP1 inhibitors in blocking β-cell apoptosis in human islets with physiologically more relevant properties for human disease, human islets isolated from nondiabetic organ donors were treated with USP1 inhibitors ML323 and SJB2-043 and then exposed to the diabetogenic milieu of glucolipotoxicity and pro-inflammatory cytokines IL-1β and IFN-γ. Caspase-3 cleavage triggered by high glucose/palmitate as well as by the mixture of cytokines was counteracted by ML323 in isolated human islets, confirmed independently by four batches of human islet preparations ([Figures 4](#fig4){ref-type="fig"}A--4D). Similar data were obtained using SJB2-043 as approach to target USP1 in isolated human islets ([Figures 4](#fig4){ref-type="fig"}E--4H). To confirm protection from apoptosis, *in situ* TUNEL together with insulin double-staining was performed to validate our Western blot data on the level of β-cells. Again, both USP1 inhibitors ML323 and SJB2-043 fully protected human islet β-cells from apoptosis induced by prolonged exposure to elevated glucose/palmitate and to the mixture of cytokines ([Figures 4](#fig4){ref-type="fig"}I and 4J), confirming the promising efficacy of USP1 inhibitors in rescuing human β-cells from apoptosis. Although strategies to interfere with the intracellular cell death mechanisms to halt β-cell failure in diabetes are highly promising, they should not compromise the insulin secretory function of pancreatic β-cells. As previously reported, modulation of key endogenous anti-apoptotic proteins in β-cells impairs β-cell function ([@bib43]). Therefore, we sought to determine whether the chemical blockade of USP1 has any impact on insulin secretion and expression of key β-cell maturation and identity genes. Therefore, we probed the influence of USP1 inhibition on the ability of human islets to secrete insulin in response to glucose. Human islets treated with ML323 and SJB2-043 showed no alteration in the intracellular insulin content ([Figure 5](#fig5){ref-type="fig"}A), and glucose-stimulate insulin secretion (GSIS) was maintained ([Figures 5](#fig5){ref-type="fig"}B and 5C), indicating that USP1 inhibition does not affect the human islet insulin secretory function. To determine whether USP1 inhibitors caused a loss of β-cell identity or de-differentiation, expression of functional genes, including insulin (*INS*), key β-cell transcription factors (*PDX1*, *NEUROD1*, *NKX2.2*, and *NKX6.1*), as well as the critical β-cell glucose transporter (*SlC2A2*), were measured by reverse transcription polymerase chain reaction (RT-PCR) in human islets. Our data showed that not only all genes were preserved in USP1 inhibitors-treated human islets cells but also *NEUROD1* and *PDX1* were significantly increased by ML323 ([Figure 5](#fig5){ref-type="fig"}D), suggesting full preservation of β-cell function and functional identity genes upon inhibition of USP1 in human islets. Our data show that inhibition of USP1 efficiently blocked human β-cell apoptosis without compromising function.Figure 4Inhibition of USP1 Promotes β-Cell Survival in Isolated Human Islets(A--J) Isolated human islets (150--200 islets/dish) treated with or without USP1 inhibitors ML323 or SJB2-043 were exposed to a mixture of 22.2 mM glucose and 0.5 mM palmitate (HG/Pal) (A, B, E, F, I, and J) or to pro-inflammatory cytokines (2 ng/mL recombinant human IL-1β and 1000 U/mL IFN-γ; Cyto; C, D, G--J) for 2 days. Representative Western blots and quantitative densitometry analysis of cleaved caspase 3 (Cl Casp3) protein levels are shown. (G) All lanes are from the same gel but were run noncontiguously. (I and J) Human pancreatic islets were fixed, paraffin embedded, and stained for the TUNEL assay and insulin. Representative images (I) and quantitative percentage of TUNEL-positive β-cells (J) are shown. Scale bars represent 50 μm. Data are pooled from at least three human islet preparations. Data show means ±SEM. \*p \< 0.05 stimuli treated compared with control conditions. \*\*p \< 0.05 inhibitor-treated compared with treated conditions.Figure 5Impact of USP1 Inhibition on Insulin Content, Secretion, and Expression of Functional β-Cell Genes in Isolated Human Islets(A--D) Isolated human islets were treated with or without USP1 inhibitors ML323 or SJB2-043 for 2 days (30 islets/dish for A--C; 150--200 islets/dish for D). (A) Insulin content analyzed after GSIS and normalized to whole islet protein. (B) Insulin secretion during 1-hr incubation with 2.8 (basal) and 16.7 mM glucose (stimulated), normalized to insulin content. (C) The insulin stimulatory index denotes the ratio of secreted insulin during 1-hr incubation with 16.7 and 2.8 mM glucose. (D) RT-PCR for *NEUROD1*, *INS, PDX1*, *NKX2.2*, *NKX6.1*, and *SlC2A2,* normalized to cyclophilin. Tubulin normalization delivered similar results. Pooled data are from four independent experiments from four different human islet donors. Data show means ±SEM. \*p \< 0.05 compared with control conditions.

USP1 Inhibition Suppressed the DNA Damage Response in Pancreatic β-cells {#sec2.4}
------------------------------------------------------------------------

Complex intracellular networks, namely, the DDR, monitor genome integrity and stability by sensing DNA damage and controlling DNA repair pathways and damage tolerance processes ([@bib63]). In principle, if the level of DDR is greater than the cellular capacity, programmed cell death is activated to prevent cellular mutations and related abnormalities that contribute to tumorigenesis. However, DDR dysregulation leads to multiple pathological settings: extensive impairment of DDR leads to cancer with uncontrolled cell overgrowth, whereas extensive upregulation may precede neurodegenerative and metabolic diseases with specific cell loss ([@bib32], [@bib74]). Several lines of evidence support the important function of USP1 in DDR processes ([@bib15], [@bib55], [@bib57], [@bib75]). As DDR markers are highly elevated in human and rodent diabetic islets/β-cells *in vitro* and *in vivo* and correlate with β-cell death ([@bib5], [@bib29], [@bib56], [@bib60], [@bib59], [@bib81]), we sought to determine whether USP1 inhibition would modulate DDR under diabetic conditions. Histone H2AX is a histone H2A variant, which is essential for cell cycle arrest and activation of DNA repair processes upon double-stranded DNA breaks. Upon DNA damage, H2AX is rapidly phosphorylated at Ser139 by PI3K-like kinases, including ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related protein (ATR), and DNA-dependent protein kinase (DNA-PK), and its phosphorylation generally referred to as γ-H2AX is universally considered as robust readout of DDR ([@bib86]). Consistent with previous studies ([@bib5], [@bib29], [@bib56], [@bib60], [@bib59], [@bib81]), glucolipotoxicity and pro-inflammatory cytokines strongly induced DDR (represented by γ-H2AX formation; [Figures 6](#fig6){ref-type="fig"}A and 6B) in INS-1E β-cells. USP1 knockdown significantly blocked γ-H2AX upregulation, correlating with its anti-apoptotic action in response to diabetogenic stimulation ([Figures 6](#fig6){ref-type="fig"}A and 6B). Consistently, both USP1 inhibitors ML323 and SJB2-043 markedly reduced γ-H2AX in all tested diabetic conditions ([Figures 6](#fig6){ref-type="fig"}C--6F). To confirm β-cell-specific regulation of DDR by USP1 inhibition in human islets, we quantified the number of γ-H2AX-positive β-cells in human islets treated with the diabetogenic milieu in the absence and presence of ML323 and SJB2-043. Glucolipotoxicity induced a number of γ-H2AX positive β-cells, whereas USP1 inhibitors significantly reduced it ([Figures 6](#fig6){ref-type="fig"}G and 6H), suggesting the β-cell-specific suppression of γ-H2AX in human islets. Transcription factor p53 is activated in response to several cellular stresses, including DNA damage, and plays a key function in coordinating cell-intrinsic responses to exogenous and endogenous stressors by promoting cell cycle arrest, senescence, and apoptosis ([@bib50], [@bib66]). P53 phosphorylation at serine 15 is the primary event during DDR (phosphorylated by DDR-related kinases ATM and ATR), which promotes both the accumulation and functional activation of p53 and is the surrogate readout of DDR activation ([@bib42], [@bib50], [@bib51]). To further test the efficacy of USP1 inhibition to suppress DDR, we quantified the number of p-p53 (at Ser15)-positive β-cells in isolated human islets treated with USP1 inhibitors exposed to the diabetic conditions. The number of p-p53-positive β-cells increased in glucose/palmitate-treated human islets, whereas both ML323 and SJB2-043 reduced such p-p53-positive cells ([Figures 6](#fig6){ref-type="fig"}I and 6J). Also, chronically elevated glucose-induced p-p53 upregulation was strongly inhibited by USP1 knockdown in INS-1E cells ([Figure 6](#fig6){ref-type="fig"}K). In addition, glucose/palmitate-induced p53 phosphorylation was fully blunted in the presence of SJB2-043 ([Figure 6](#fig6){ref-type="fig"}L) in human islets, further supporting the attenuation of DDR markers in diabetic β-cells by USP1 inhibition.Figure 6Inhibition of USP1-Suppressed DDR(A, B, and K) INS-1E cells seeded at 300,000 cells/well were transfected with either control siScr or siUSP1 and treated with a mixture of 22.2 mM glucose and 0.5 mM palmitate (HG/Pal) or pro-inflammatory cytokines (2 ng/mL recombinant human IL-1β, 1000 U/mL TNF-α, and 1000 U/mL IFN-γ; Cyto). Representative Western blot (A and K) and quantitative densitometry analysis (B) of γ-H2AX and p-p53 proteins are shown.(C--F) About 500,000 INS-1E cells/well treated with or without USP1 inhibitors ML323 (C and D) or SJB2-043 (E and F) were exposed to a mixture of 22.2 mM glucose and 0.5 mM palmitate (HG/Pal; C), 22.2 mM glucose (HG; E), or pro-inflammatory cytokines (2 ng/mL recombinant human IL-1β, 1000 U/mL TNF-α, and 1000 U/mL IFN-γ; Cyto; D and F) for 2 days. Data are pooled from at least three independent cell line experiments. Tubulin loading control in [Figure 5](#fig5){ref-type="fig"}F is re-used from the same experiment shown in [Figure 3](#fig3){ref-type="fig"}F.(G--J and L) Isolated human islets (150--200 islets/dish) treated with or without USP1 inhibitors ML323 or SJB2-043 were exposed to a mixture of 22.2 mM glucose and 0.5 mM palmitate (HG/Pal) for 2 days. (G--J) Human pancreatic islets were fixed, paraffin embedded, and stained for γ-H2AX (G) or p-p53 (I) and insulin. Representative images (G and I) and quantitative percentage of γ-H2AX or p-p53-positive β-cells (H and J) are shown. Scale bars represent 50 μm. Data are pooled from three human islet preparations except for J (n = 2). (L) Representative Western blot of p-p53 protein is shown. All lanes are from the same gel but were run noncontiguously.Data show means ±SEM. \*p \< 0.05 stimuli treated compared with control conditions. \*\*p \< 0.05 inhibitor-treated compared with treated conditions.

USP1 Inhibition Improves Survival and Lowers DDR in Diabetic β-cells {#sec2.5}
--------------------------------------------------------------------

A progressive impairment of β-cell function together with increased β-cell death under diabetic conditions has been clearly documented in human β-cells. To test the potential beneficial effect of USP1 suppression in the human β-cell under conditions of T2D, we performed a proof-of-concept experiment, whereby we inhibited USP1 in two human islet preparations isolated from two patients with T2D. Islets were treated with ML323 and SJB2-043 for 24 hr. Consistent with the improved β-cell survival of human islets under diabetogenic conditions upon USP1 inhibition, isolated T2D islets treated with both USP1 inhibitors showed less apoptotic β-cells, demonstrated in two independent experiments from two different T2D human islet isolations ([Figure 7](#fig7){ref-type="fig"}A). In line with our data in INS-1E cells and human islets, both ML323 and SJB2-043 treatment highly reduced the number of γ-H2AX- and p-p53-positive β-cells in human islets consistently in two distinct human T2D islet batches ([Figures 7](#fig7){ref-type="fig"}B and 7C). This further confirms the USP1-dependent regulation of DDR under a diabetic environment.Figure 7USP1 Inhibitors Reduced β-Cell Apoptosis and DDR in Human T2D IsletsIsolated human islets from two patients with T2D treated with or without USP1 inhibitors ML323 or SJB2-043 for 1 day. (A--C) Human pancreatic islets were fixed, paraffin embedded, and double stained for the TUNEL assay (A), γ-H2AX (B), or p-p53 (C) and insulin. Representative confocal images and individual quantitative percentage of TUNEL, γ-H2AX, or p-p53 positive β-cells are shown from 2 to 4 technical replica/group from two islet donors with confirmed T2D. Scale bars represent 50 μm. Data are means of TUNEL-, γ-h2AX-, or pp53- and insulin-co-positive β-cells from pooled data of 2--4 different human islet sections spanning the whole islet pellet for each experimental group. About 150--200 islets were plated for each group. The mean number of β-cells scored was 6,050 for each condition for each donor.

Discussion {#sec3}
==========

Loss of insulin-producing pancreatic β-cells results in hyperglycemia and is the hallmark of both T1D and T2D. Identification of key signaling molecules that promote β-cell death in diabetes, together with an understanding of their mechanisms of action, is critical for the disease pathogenesis as well as for novel therapeutic interventions to halt β-cell failure during development and progression of diabetes. This study provides the first direct evidence that genetic or pharmacological inhibition of the enzyme USP1 protects β-cells from apoptosis under diabetogenic stimulation by attenuating DDR signals.

DDR is a signal transduction pathway, which functions together with other networking pathways known as DNA damage checkpoints ([@bib26]), and its dysregulation is a hallmark of several pathological disorders, such as cancer and neurodegenerative and metabolic diseases ([@bib32], [@bib74]). Elevated DDR has been observed in pancreatic islets/β-cells under increased cellular stress and metabolic demand *in vivo* or under diabetic conditions *in vitro*. Surrogate markers of DDR, such as γ-H2AX, p53, and P53BP1, are highly upregulated in primary islets and β-cells in response to oxidative and inflammatory assaults as well as in pancreatic islets from streptozotocin (STZ)-treated diabetic mice, leptin-receptor-deficient *dbdb*, and human T2D islets ([@bib5], [@bib29], [@bib56], [@bib60], [@bib59], [@bib81]), suggesting that oxidative- or metabolic-mediated double-strand breaks in the DNA and downstream activation of p53 may be a key pathogenic element of β-cell stress under metabolic and inflammatory conditions. This is further supported by the elevated incidence of diabetes in individuals who received irradiation to the pancreas ([@bib16], [@bib49]). Furthermore, oxidized DNA and p53 signaling are both highly upregulated in human T2D islets ([@bib72], [@bib81]). Initially, the DDR coordinates a transcriptional program with DNA repair and cell cycle arrest ([@bib11]); however, under sustained cellular stresses when DNA damage can no longer be repaired, the DDR initiates apoptosis ([@bib70]). DUBs play an important role in DDR. Although multiple numbers of DUBs are involved in DNA repair and the downstream process, USP1 is the first enzyme characterized as the key player in DDR ([@bib33]). USP1 is the DUB responsible for deubiquitination of monoubiquitinated FANCD2 ([@bib55]), an integral component of the Fanconi anemia (FA) DNA repair pathway and PCNA ([@bib36]). USP1 and its associated partner USP1-associated factor 1 (UAF1) play an important function in promoting DNA homologous recombination (HR) repair in response to DDR via distinct mechanisms: through FANCD2 deubiquitination ([@bib55]) or by interacting with RAD51 associated protein 1 (RAD51AP1; [@bib15]). It is possible that the interactions with these known USP1 targets directly lead to the reduced γ-H2AX described in our study. Also, USP1-dependent regulation of other signaling pathways such as AKT ([@bib90], [@bib92]) or upstream elements of the DDR, such as CHK1, a key kinase involved in DDR and DNA repair, which is also stabilized by USP1 ([@bib24]), may affect the DDR output together with γ-H2AX formation ([@bib6], [@bib76], [@bib84]). Owing to the complexity of DDR signaling and multi-layer actions of USP1, there may also be dual and time-/concentration-/cell-system-dependent effects on γ-H2AX formation or on DDR in general, as an induction of γ-H2AX upon USP1 inhibition has also been observed ([@bib58]). Our results suggest that the genetic and pharmacological suppression of USP1 in rodent β-cell and human islets protected the cells from DNA-damage-induced cell death with preserving β-cell insulin secretion and β-cell key maturation genes, proposing the critical function of USP1 in the regulation of β-cell apoptosis under different diabetogenic conditions. However, pathway(s) responsible for the regulation of USP1 as well as the molecular mechanism by which USP1 regulates DDR in β-cells, especially in the diabetic environment, remains unknown and warrants further mechanistic investigations.

Although several USP1 targets, such as FANCD2 and PCNA, have been established in the context of DDR, the identification of novel USP1 substrates in other cellular processes will provide further insights on the action of USP1 in regulating cell survival and stress response. Recently, TANK-binding kinase 1 (TBK1), a key regulator of the innate antiviral immunity and maintenance of immune homeostasis, has been discovered as a novel substrate of USP1 ([@bib85]). Yu et al. showed that USP1 functions as an important cellular enhancer of Toll-like receptor 3/4 (TLR3/4)-, retinoic acid-inducible gene I (RIG-I)-, and cyclic GMP-AMP synthase (cGAS)-induced antiviral signaling by TBK1 deubiquitination and regulation of its stability ([@bib85]). TBK1 has a pleotropic function in the metabolic process, inflammation, and diabetes. Identified as an inflammatory kinase that targets the insulin receptor ([@bib54]), TBK1 regulates insulin-stimulated glucose uptake in adipocytes ([@bib82]). TBK1 levels are upregulated in obesity and diabetes, and the inhibition of TBK1 together with another inflammatory IKK-related kinase IKKɛ by the dual kinase inhibitor amlexanox reduces weight, fatty liver, and inflammation, as well as promotes insulin sensitivity in obese diabetic mice ([@bib65]) and presents a significant reduction in HbA1c in a subset of patients with T2D ([@bib61]). As diabetogenic conditions, such as elevated palmitic acid, induce β-cell death and dysfunction at least in part through TLR4 signals ([@bib19], [@bib71]) upstream of TBK1, it is likely that the newly identified USP1-TBK1 axis affects viability, stress response, and inflammation in β-cells as well as in other metabolically active tissues in metabolic and inflammatory contexts. This remains to be investigated.

Conclusion {#sec3.1}
----------

Impaired β-cell survival is a key pathogenic element of pancreatic β-cell\'s insufficiency in both T1D and T2D. Here we demonstrated the anti-apoptotic action of USP1 inhibition through the regulation of DDR in several *in vitro* and *ex vivo* experimental models of diabetes in stressed β-cells in both rodent and human cells. The identification of the previously uncharacterized function of USP1 in the regulation of β-cell apoptosis may have a potential therapeutic relevance for the preservation of functional β-cell mass in diabetes. To warrant this, identification of β-cell-specific USP1 substrates, detailed mechanistic analyses, as well as the *in vivo* preclinical assessment of utility, efficacy, and side effects of currently available USP1 inhibitors are required in the near future.
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